Soluble endoglin, transforming growth factor-beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Perucci, Luiza O ^a   Gomes, Karina B ^a   Freitas, Letícia G ^a   Godoi, Lara C ^a   Alpoim, Patrícia N ^a   Pinheiro, Melina B ^a,b   Miranda, Aline S ^a   Teixeira, Antônio L ^a   Dusse, Luci M ^a   Sousa, Lirlândia P ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; ENDOGLIN; LACTATE DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY; PROTEIN DETERMINATION; PROTEIN FUNCTION; YOUNG ADULT; BLOOD; PATHOPHYSIOLOGY;

ANTIGENS, CD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84901327137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097632     Document Type: Article

References (54)

1. Schroeder BM (2002) ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American College of Obstetricians and Gynecologists. Am Fam Physician 66: 330-331.
2. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, et al. (1995) Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173: 1042-1048.
3. Sibai BM (2008) Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 52: 805-806.
4. Eiland E, Nzerue C, Faulkner M (2012) Preeclampsia 2012. J Pregnancy 2012: 586578.
5. Marques FK, Campos FM, Filho OA, Carvalho AT, Dusse LM, et al. (2012) Circulating microparticles in severe preeclampsia. Clin Chim Acta 414: 253-258.
6. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ (1999) Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 106: 1019-1022. (Pubitemid 29457082)
7. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649. (Pubitemid 43865232)
8. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005. (Pubitemid 44343543)
9. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, et al. (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87: 837-842.
10. Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274: 584-594.
11. Luft FC (2006) Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 21: 3052-3054.
12. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N (2003) Maternal plasma levels of cytokines in normal and preeclamptic pregnancies and their relationship with diastolic blood pressure and fibronectin levels. Acta Obstet Gynecol Scand 82: 797-802. (Pubitemid 37082907)
13. Ayatollahi M, Geramizadeh B, Samsami A (2005) Transforming growth factor beta-1 influence on fetal allografts during pregnancy. Transplant Proc 37: 4603-4604. (Pubitemid 43016091)
14. Saito S, Nakashima A, Shima T, Ito M (2010) Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 63: 601-610.
15. Redman CW, Sacks GP, Sargent IL (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180: 499-506. (Pubitemid 29093892)
16. Pinheiro MB, Martins-Filho OA, Mota AP, Alpoim PN, Godoi LC, et al. (2013) Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. Cytokine 62: 165-173.
17. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW (1995) Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 102: 20-25.
18. Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH (2009) First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound Obstet Gynecol 33: 135-141.
19. Sibai B, Romero R, Klebanoff MA, Rice MM, Caritis S, et al. (2009) Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol 200: 630.e631-638.
20. Blanco JC, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, et al. (2004) The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res 24: 21-28. (Pubitemid 38147263)
21. Burtis CA, Ashwood ER, Bruns DE, editors (2006) Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St. Louis: Elsevier Saunders. 2448 p.
22. Hertig A, Fort J, Lefevre G, Chabbert-Buffet N, Uzan M, et al. (2010) Soluble endoglin in preeclamptic patients with or without HELLP syndrome. Am J Obstet Gynecol 202: 594.e591-594.
23. Peraçoli MT, Menegon FT, Borges VT, de Araújo Costa RA, Thomazini-Santos IA, et al. (2008) Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia. J Reprod Immunol 79: 79-84.
24. Robinson CJ, Johnson DD (2007) Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 197: 174.e171-175.
25. Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, et al. (2003) CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 116: 2677-2685. (Pubitemid 36857221)
26. Jerkic M, Rivas-Elena JV, Prieto M, Carrón R, Sanz- Rodríguez F, et al. (2004) Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 18: 609-611.
27. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y (2007) Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 92: 2672-2679. (Pubitemid 47037375)
28. Staff AC, Harsem NK, Braekke K, Hyer M, Hoover RN, et al. (2009) Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Eur J Obstet Gynecol Reprod Biol 143: 29-33.
29. Chaiworapongsa T, Romero R, Kusanovic JP, Mittal P, Kim SK, et al. (2010) Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 35: 155-162.
30. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT (2009) The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29: 464-470.
31. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, et al. (2010) Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 117: 314-320.
32. Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, et al. (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 199: 653.e651-610.
33. Zhang LJ, Han YH, Han YZ (2010) [Serum soluble Endoglin, plasma endothelin-1 and coagulation function in early onset severe preeclampsia with organ dysfunction]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 22: 371-374.
34. Tjwa M, Luttun A, Autiero M, Carmeliet P (2003) VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 314: 5-14. (Pubitemid 37409908)
35. Szarka A, Rigó J, Lázár L, Beko G, Molvarec A (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 11: 59.
36. Feizollahzadeh S, Taheripanah R, Khani M, Farokhi B, Amani D (2012) Promoter region polymorphisms in the transforming growth factor beta-1 (TGFβ1) gene and serum TGFb1 concentration in preeclamptic and control Iranian women. J Reprod Immunol 94: 216-221.
37. Lev PR, Salim JP, Marta RF, Osorio MJ, Goette NP, et al. (2007) Platelets possess functional TGF-beta receptors and Smad2 protein. Platelets 18: 35-42.
38. Gil-Villa AM, Norling LV, Serhan CN, Cordero D, Rojas M, et al. (2012) Aspirin triggered-lipoxin A4 reduces the adhesion of human polymorphonuclear neutrophils to endothelial cells initiated by preeclamptic plasma. Prostaglandins Leukot Essent Fatty Acids 87: 127-134.
39. Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS (1990) Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 171: 2025-2041. (Pubitemid 20200241)
40. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, et al. (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 89: 4845-4849.
41. Arntzen KJ, Liabakk NB, Jacobsen G, Espevik T, Austgulen R (1995) Soluble tumor necrosis factor receptor in serum and urine throughout normal pregnancy and at delivery. Am J Reprod Immunol 34: 163-169.
42. Austgulen R, Liabakk NB, Lien E, Espevik T (1993) Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns. Pediatr Res 33: 82-87. (Pubitemid 23094132)
43. Opsjøn SL, Novick D, Wathen NC, Cope AP, Wallach D, et al. (1995) Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. J Reprod Immunol 29: 119-134.
44. Lau SY, Guild SJ, Barrett CJ, Chen Q, McCowan L, et al. (2013) Tumor Necrosis Factor-Alpha, Interleukin-6, and Interleukin-10 Levels are Altered in Preeclampsia: A Systematic Review and Meta-Analysis. Am J Reprod Immunol 70: 412-427.
45. Hupuczi P, Nagy B, Sziller I, Rigó B, Hruby E, et al. (2007) Characteristic laboratory changes in pregnancies complicated by HELLP syndrome. Hypertens Pregnancy 26: 389-401. (Pubitemid 350232903)
46. Tracey KJ, Cerami A (1993) Tumor necrosis factor: an updated review of its biology. Crit Care Med 21: S415-422. (Pubitemid 23304331)
47. Anderson HD, Rahmutula D, Gardner DG (2004) Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 279: 963-969. (Pubitemid 38082617)
48. Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88: 4651-4655. (Pubitemid 21914599)
49. Halim A, Kanayama N, El Maradny E, Maehara K, Takahashi A, et al. (1996) Immunohistological study in cases of HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) and acute fatty liver of pregnancy. Gynecol Obstet Invest 41: 106-112. (Pubitemid 26055561)
50. Lastres P, Bellon T, Cabañas C, Sanchez-Madrid F, Acevedo A, et al. (1992) Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22: 393-397.
51. Torsney E, Charlton R, Parums D, Collis M, Arthur HM (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51: 464-470. (Pubitemid 35034452)
52. Rossi E, Sanz-Rodriguez F, Eleno N, Düwell A, Blanco FJ, et al. (2013) Endothelial endoglin is involved in inflammation: role in leukocyte adhesion and transmigration. Blood 121: 403-415.
53. Scharpfenecker M, Floot B, Russell NS, Stewart FA (2012) The TGF-β co-receptor endoglin regulates macrophage infiltration and cytokine production in the irradiated mouse kidney. Radiother Oncol 105: 313-320.
54. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, et al. (2010) The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 23: 911-916.